Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
FDA
Biotech
Biohaven epilepsy drug suffers FDA hold days after $350M deal
The FDA has put enrollment in trials of Biohaven’s epilepsy drug candidate BHV-7000 on hold in response to findings from rodent tests.
Nick Paul Taylor
Sep 10, 2026 10:03am
Fierce Pharma
FDA's surprise approval of AZ's oral SERD sets new paradigm
Sep 8, 2026 10:35am
FDA says Boston Scientific recalls spinal cord implant
Sep 8, 2026 8:14am
SEC, FDA sign MOU as a ‘signal to the market’ on insider trading
Sep 2, 2026 10:15am
Medtronic recalls reflux device amid 184 serious injuries
Sep 1, 2026 9:41am
Boston Scientific halts sales of angiographic catheters
Sep 1, 2026 8:42am
